The Senate Finance Committee today held a hearing on strategies to reduce prescription drug costs and encourage innovation and competition in the market. Health and Human Services Secretary Alex Azar testified on the administration’s blueprint to lower drug prices, released in May. In a statement submitted to the committee, AHA urged Congress to pass the Creating and Restoring Equal Access to Equivalent Samples Act to prevent anticompetitive behaviors used to block and delay entry of generic drugs; and H.R. 4392 to prevent a 30% reduction in Medicare payment to certain hospitals for outpatient drugs purchased under the 340B drug savings program, among other actions. Hospital spending on inpatient drugs increased 38.7% per admission between 2013 and 2015, more than three times the increase in spending for retail prescription drugs over the period, the statement notes.

Related News Articles

Last week, I shared a few areas where we can advance health in America this year, even in a divided Congress.
Continued rising drug prices, as well as shortages for many critical medications, are disrupting patient care and forcing hospitals to delay infrastructure and…
Chairperson's File
When our paths cross in the year ahead, I ask you to share what is on your mind, what keeps you up at night, and how we can work together to ensure that all…
We’re 11 days into 2019 … we’ve returned to a divided government …and the partial government shutdown continues.
Insights and Analysis
Also in this weekly roundup of health news: AHA president and CEO Rick Pollack speaks to HealthLeaders about the association’s year ahead; digital health…
As Congress prioritizes action to lower drug prices, the Campaign for Sustainable Rx Pricing yesterday announced a website to help lawmakers and their staff…